We are live on ! Find out more

LENZ

LENZ Therapeutics

LENZ

Market cap $142M

4.47 USD

-0.05

1.11%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

4.46

-0.01

0.22%

1 day

-1.11%

5 days

-24.87%

1 month

-5.5%

3 months

-32.58%

6 months

-61.93%

Year to date

-72.06%

1 year

-88.83%

5 years

-96.72%

10 years

-96.55%

About: LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

Employees: 152

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 7.7%

Neutral 84.6%

Negative 7.7%

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

LENZ Therapeutics: Still Speculative But Priced For Disasters

LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited.

LENZ Therapeutics: Still Speculative But Priced For Disasters

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ).

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics Q2 Earnings Call Highlights

LENZ Therapeutics NASDAQ: LENZ reported second-quarter revenue of $5.5 million as it continued the commercial launch of VIZZ, citing modest quarterly growth and a pickup in prescription activity following the July rollout of national television advertising and a telehealth access option.

LENZ Therapeutics Q2 Earnings Call Highlights

Zacks Investment Research

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to a loss of $0.53 per share a year ago.

LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Q2 2026 total revenue of $5.5 million from VIZZ product sales and global license agreements Strong patient persistence, with over 60% of patients in our dominant ePharmacy channel purchasing multiple monthly packs since launch, tracking to five packs annually VIZZ prescription growth accelerated with launch of telehealth channel in July 2026 Management to host conference call today, August 11, 2026, at 4:30 p.m. EDT SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported financial results for the second quarter ended June 30, 2026, and recent corporate highlights.

LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights.

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

See News Rankings

Price charts implemented using Lightweight Charts™